Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Sanofi India Ltd

₹ 4,1653.58%
16 Jan 3:40 p.m. – close price
🔗sanofiindialtd.com•BSE: 500674•NSE: SANOFI
Market Cap₹ 9,592 Cr.
Current Price₹ 4,165
High / Low₹ 6,718
Stock P/E26.0
Book Value₹ 340
Dividend Yield2.82 %
ROCE49.2 %
ROE47.2 %
Face Value₹ 10.0
Sales₹ 1,932 Cr.
OPM26.9 %
Mar Cap₹ 9,592 Cr.

ABOUT

Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.[1]

KEY POINTS

Parent Company[1]Sanofi Global and its 100% subsidiary - Hoechst GmbH, are the shareholders of Sanofi India and together hold 60.40%. Company's follows parent company's financial year hence,Financial year is same as Calender Year.

Also present in buckets:
Excellent ResultsCapacity Expansion And ProductsJv Partnerships AcquisitionsRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1669.2034.64400497.060.953124.952.5614478.318.9320.2154964.0130.1211543.963117.955.1112.970.07
2.Divi's Lab.6233.9566.60165491.740.47689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.7113.530.01
3.Torrent Pharma.4018.7562.76136012.730.81591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.1213.260.33
4.Cipla1399.4020.77113039.590.941353.373.737589.447.6422.7228349.5725.405441.141351.173.3914.720.01
5.Lupin2174.2023.0799317.100.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.0812.410.32
6.Dr Reddy's Labs1179.3017.0898427.950.671336.807.288828.309.8322.6934310.0024.645772.201347.102.7412.950.16
7.Mankind Pharma2173.5551.3589725.230.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.515.968.890.55
8.Sanofi India4165.0025.999592.022.8276.0015.54475.40-9.2749.161932.5026.87369.2994.9712.2526.590.03
–Median: 149 Co.390.630.091763.550.1113.4911.71161.7610.5814.89591.7315.9345.2613.963.078.560.22

Quarterly Results

Standalone figures in ₹ crores

Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
692672736515491469511464524515536406475
Expenses
510505507393377370374348404397364311341
Operating Profit
18216723012211410013711612011817295134
Other Income
113444578277412121439-22
Profit before tax
18219026416918616716912711312216594102
Tax %
28%31%28%27%18%18%19%19%27%25%28%26%26%
Net Profit
13113119012315213813710382911207076
EPS in Rs
56.9156.9182.7853.4366.1759.8759.3944.9635.7439.7051.9630.2233.04

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024TTM
Sales
1,8091,9772,1932,3672,4602,7713,0712,9022,9572,7701,9962,0131,932
Expenses
1,4111,6391,8171,8321,9212,1462,4032,1862,1942,0661,5081,5221,413
Operating Profit
398339376535538625667716762704488491519
Other Income
831312186679883345564204318794
Interest
0002110222222
Depreciation
9297113119102103100826742363737
Profit before tax
3883734814805156106006771,258864767531484
Net Profit
265264322304326381414478944621603414356
EPS in Rs
115.30114.61139.78132.26141.74165.48180.09207.65410.61269.83262.26179.78154.92
Dividend Payout %
39%39%46%51%50%51%194%176%119%211%64%65%–

Compounded Sales Growth

10 Years:0%
5 Years:-8%
3 Years:-12%
TTM:-2%

Compounded Profit Growth

10 Years:8%
5 Years:0%
3 Years:-9%
TTM:4%

Stock Price CAGR

10 Years:5%
5 Years:-5%
3 Years:5%
1 Year:-26%

Return on Equity

10 Years:24%
5 Years:32%
3 Years:41%
Last Year:47%

Balance Sheet

Standalone figures in ₹ crores

Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Jun 2025
Equity Capital
23232323232323232323232323
Reserves
1,3241,4631,6041,8602,0032,1962,4192,0962,2031,253992838759
Borrowings
0000000232524191921
Other Liabilities
532742778658751765802777811772681732436
Total Liabilities
1,8782,2282,4052,5412,7782,9843,2442,9183,0612,0721,7151,6121,239
Fixed Assets
699648877817769733499464334306315312309
Gross Block
1,102.181,132.111,454.20935.70989.101,053.30817.10851.70546.30530.90543.60560.80–
Accumulated Depreciation
403.63483.75577.10118.80220.10320.50318.40387.60212.20225.40228.70248.30–
CWIP
1362102234302117101324161816
Investments
0000000000200
Other Assets
1,0431,3691,5051,6901,9782,2302,7282,4442,7141,7431,3821,281914
Total Assets
1,8782,2282,4052,5412,7782,9843,2442,9183,0612,0721,7151,6121,239

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operating Activity
273265213322435374412611559399231462
Cash from Investing Activity
-3356136-155-79-736627663165136-178
Cash from Financing Activity
-105-122-147-180-188-197-183-810-849-1,583-878-392
Net Cash Flow
-168205102-1316810429578341-533-612-109

Ratios

Standalone Figures in ₹ Crores / Yearly

Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Debtor Days
242124222921271918172442
Inventory Days
151179173169151154127107110125254186
Days Payable
83122817911911010093105109112151
Cash Conversion Cycle
927811511261655433223316777
Working Capital Days
4326979171835-8-20-193520
ROCE %
29%22%26%27%26%29%28%32%35%41%44%49%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%60.40%
FIIs
6.99%6.71%6.72%6.80%6.31%6.11%5.81%5.78%5.64%5.58%5.61%5.57%
DIIs
19.22%19.46%19.65%21.68%22.51%22.88%22.60%22.62%22.94%23.02%23.06%22.28%
Public
13.41%13.43%13.22%11.10%10.78%10.61%11.21%11.20%11.04%11.01%10.94%11.75%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Sanofi India Submits RTA Certificate for Securities Dematerialization

10th April 2026, 3:11 am

Sanofi India Announces 70th AGM Details, Integrated Annual Report, and Dividend Information

3rd April 2026, 9:43 pm

Sanofi India Announces 70th AGM Date, Rs. 48 Dividend, and Annual Report Dispatch

3rd April 2026, 1:23 am

Sanofi India Recommends Final Dividend of Rs. 48 Per Share; Outlines TDS Rules

3rd April 2026, 1:25 am

Central Government approves Deepak Arora's appointment as Sanofi India MD for 3 years

3rd April 2026, 1:18 am

Published by Other Websites

External media mentions & references

April Dividend Rush: Vedanta, Crisil Payouts Near for Investors

31st March 2026, 10:56 am

Kedaara Capital Eyes ₹3,000 Crore Sale of Nutraceutical Firm Universal NutriScience

11th March 2026, 1:09 am

Sanofi India Elevates Legal Head Sudipta Chakraborty to Board

26th February 2026, 7:34 pm

Tejas Networks Surges 15%, Sanofi Consumer Jumps as Indian Markets Show Caution

26th February 2026, 2:36 pm

Sanofi India Shares Dive Amid Weak Earnings; Consumer Unit Surges 14%

26th February 2026, 10:10 am

News Articles

Editorial & research coverage

India Budget 2026: Drug Duty Cuts Offer Targeted Relief
India Budget 2026: Drug Duty Cuts Offer Targeted Relief

3rd February 2026, 11:08 am

India Pharma Surges 8.6%! But What's Behind The Growth & Which Stocks Are Winning (And Losing)?
India Pharma Surges 8.6%! But What's Behind The Growth & Which Stocks Are Winning (And Losing)?

15th December 2025, 5:27 pm

Dividend Stocks in Focus: 17 Companies Including Hindustan Unilever and BPCL Trade Ex-Dividend on November 7
Dividend Stocks in Focus: 17 Companies Including Hindustan Unilever and BPCL Trade Ex-Dividend on November 7

6th November 2025, 8:55 am

Documents

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication

9 Jan - Copies of the Notice to Shareholders of the Company published today i.e. 9th January 2026, in newspapers, Business Standard (English) and Sakal (Marathi).

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

5 Jan - Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended 31st December 2025.

Disclosure Under Regulation 30 Of SEBI (LODR) Regulation, 2015

30 Dec - 29 Dec 2025 CGST order: Rs1,43,49,690 tax and equal penalty for FY2018-19–2022-23; appeal.

Closure of Trading Window
Announcement under Regulation 30 (LODR)-Newspaper Publication

26 Dec - Copies of the Newspaper publication regarding the information on special window for re-lodgement of transfer requests of physical shares.

Annual Reports

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2013

(from nse)

Financial Year 2012

(from bse)

Financial Year 2011

(from bse)

Credit Ratings

No credit ratings.

Concalls

Nov 2025

TranscriptPPTRecording

May 2024

TranscriptPPT

Feb 2024

TranscriptPPT

Feb 2024

Transcript

Nov 2023

TranscriptPPT

Nov 2023

Transcript

May 2023

Transcript

May 2023

TranscriptPPT

Feb 2023

Transcript

Feb 2023

Transcript

Mar 2021

PPT

Stock Analysis

Description

  1. Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.[1]

Key Growth Triggers

  1. The company is focusing on its diabetes and insulin franchise, including the launch of Soliqua® and the performance of Toujeo®.
  2. Strategic partnerships aim to expand market reach in Cardiovascular and Central Nervous System segments.
  3. Operational efficiencies and AI integration are driving margin expansion and sustainable growth.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. Past news indicates receipt of several tax demand orders from various authorities concerning FY2018-19 to FY2022-23, primarily related to vendor confirmations, excess ITC claims, and ITC irregularities, though the company has stated no material impact due to prior deposits and intends to appeal.
  2. Historical company data indicates the company has delivered poor sales growth over the past five years.

Key Dates To Watch

  1. Currently no data available for Key Dates to Watch.

Corporate Announcements

9th Apr 26
Impact Rating: 3
Sanofi India Limited has officially submitted a SEBI Regulation 74(5) compliance certificate. The certificate, provided by its Registrar and Share Transfer Agent MUFG Intime India, confirms the processing of securities dematerialization for the quarter ending March 31, 2026.
3rd Apr 26
Impact Rating: -
No description available.
2nd Apr 26
Impact Rating: 7
Sanofi India Limited's 70th AGM is set for April 29, 2026, conducted virtually. Shareholders will receive the Integrated Annual Report, and a Rs. 48 per share dividend is proposed. Key dates for e-voting and dividend are announced.
2nd Apr 26
Impact Rating: 8
Sanofi India announced a recommended final dividend of Rs. 48 per equity share for FY2025, subject to AGM approval. The record date is April 22, 2026, with specific TDS implications for shareholders.
2nd Apr 26
Impact Rating: 7
Sanofi India Limited announced that the Central Government has approved the appointment of Mr. Deepak Arora as Managing Director for a term of three years, effective from October 27, 2025.